

Andrew S Poklepovic

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4318260/andrew-s-poklepovic-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

933
citations

19
h-index

29
g-index

50
ext. papers

1,261
ext. citations

5.3
avg, IF

4.59
L-index

#	Paper	IF	Citations
46	The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant.. <i>Case Reports in Obstetrics and Gynecology</i> , 2022 , 2022, 9412201	0.8	
45	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.. <i>Lancet, The</i> , 2022 ,	40	18
44	Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43. <i>Aging</i> , 2021 , 13, 17097-17117	5.6	2
43	Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2647-2655	2.2	19
42	Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib. <i>Biochemical Pharmacology</i> , 2021 , 190, 114642	6	3
41	The development of multi-kinase inhibitors as pancreatic cancer therapeutics. <i>Anti-Cancer Drugs</i> , 2021 , 32, 779-785	2.4	1
40	Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells. <i>Frontiers in Oncology</i> , 2021 , 11, 723966	5.3	1
39	Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	11
38	A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. <i>Cancer</i> , 2020 , 126, 3464-3470	6.4	10
37	Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]. <i>Cellular Signalling</i> , 2020 , 68, 109525	4.9	4
36	The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells. <i>Cellular Signalling</i> , 2020 , 70, 109573	4.9	10
35	Fingolimod Augments Monomethylfumarate Killing of GBM Cells. <i>Frontiers in Oncology</i> , 2020 , 10, 22	5.3	4
34	Metabolism of Histone Deacetylase Proteins Oponizes Tumor Cells to Checkpoint Inhibitory Immunotherapies. <i>Immunometabolism</i> , 2020 , 2,	4.1	2
33	Considering adjuvant therapy for stage II melanoma. <i>Cancer</i> , 2020 , 126, 1166-1174	6.4	12
32	AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication. <i>Biochemical Pharmacology</i> , 2020 , 182, 114227	6	19
31	The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib. <i>Frontiers in Oncology</i> , 2019 , 9, 650	5.3	9
30	Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. <i>Oncogene</i> , 2019 , 38, 5890-5904	9.2	40

29	BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. <i>Journal of Translational Medicine</i> , 2019 , 17, 386	8.5	17
28	Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, G1 and G2 and kill uveal melanoma cells. <i>Cancer Biology and Therapy</i> , 2019 , 20, 700-710	4.6	23
27	Kinase inhibitors: look beyond the label on the bottle. 2019 , 2, 1032-1043		
26	The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. <i>Cancer Biology and Therapy</i> , 2018 , 19, 132-137	4.6	25
25	The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. <i>Cancer Biology and Therapy</i> , 2018 , 19, 239-247	4.6	4
24	The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells. <i>Cancer Biology and Therapy</i> , 2018 , 19, 525-533	4.6	14
23	The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells. <i>Cancer Biology and Therapy</i> , 2018 , 19, 786-796	4.6	12
22	[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration. <i>Oncotarget</i> , 2018 , 9, 6062-6074	3.3	16
21	Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. <i>Cardio-Oncology</i> , 2018 , 4,	2.8	9
20	Prognostic Value of Low Tumor Burden in Patients With Melanoma. <i>Oncology</i> , 2018 , 32, e90-e96	1.8	9
19	Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis. <i>Case Reports in Oncological Medicine</i> , 2017 , 2017, 8095601	0.9	3
18	[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells. <i>Cancer Biology and Therapy</i> , 2017 , 18, 705-714	4.6	35
17	PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. <i>Oncotarget</i> , 2017 , 8, 1449-1468	3.3	37
16	The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. <i>Oncotarget</i> , 2017 , 8, 16367-16386	3.3	42
15	HDAC inhibitors enhance the immunotherapy response of melanoma cells. <i>Oncotarget</i> , 2017 , 8, 83155-83170	3.3	81
14	HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody. <i>Oncotarget</i> , 2017 , 8, 90262-90277	3.3	42
13	The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. <i>Oncotarget</i> , 2016 , 7, 19620-30	3.3	40
12	Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS. <i>Oncotarget</i> , 2016 , 7, 17290-300	3.3	16

11	[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFB compensatory survival signaling. <i>Oncotarget</i> , 2016 , 7, 23608-32	3.3	25
10	Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo. <i>Oncotarget</i> , 2016 , 7, 40398-40417	3.3	17
9	Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic. <i>Frontiers in Oncology</i> , 2016 , 6, 142	5.3	28
8	Nexavar/Stivarga and viagra interact to kill tumor cells. <i>Journal of Cellular Physiology</i> , 2015 , 230, 2281-98		37
7	Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1660-70	4.6	17
6	Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2384-98	6.1	37
5	Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer. <i>Autophagy</i> , 2014 , 10, 1478-80	10.2	69
4	Pazopanib and HDAC inhibitors interact to kill sarcoma cells. <i>Cancer Biology and Therapy</i> , 2014 , 15, 578-85	4.6	31
3	PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. <i>Cancer Biology and Therapy</i> , 2014 , 15, 758-67	4.6	41
2	HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. <i>Cancer Biology and Therapy</i> , 2014 , 15, 305-16	4.6	29
1	Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. <i>Investigational New Drugs</i> , 2013 , 31, 937-42	4.3	11